A Massachusetts pharmaceutical company has filed its second set of suits alleging Pfizer and Moderna violated patents when developing their coronavirus vaccines, nearly doubling the number of vaccine patent infringement claims pending against the two companies in the District of Delaware.

Alnylam Pharmaceuticals is represented in all its pending Delaware litigation by McDermott Will & Emery. The original Alnylam cases each involved one patent issued in February 2022, while the new ones, filed on March 26, claim infringement of several more all issued earlier this year.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]